India’s first new chemical entity (NCE) Lipaglyn (Saroglitazar) is discovered and developed indigenously by an Indian Pharmaceutical Company …Zydus Cadilla.

Zydus Cadilla announced a breakthrough in its research effots with Lipaglyn, a drug targeted at bridging a hitherto unmet healtcare need for treating diabetic dyslipidemia or hypertriglyceridemia in Type II diabetes, not controlled by statins.

Lipaglyn is the world’s first drug for treating diabetic dyslipdemia and combines lipid-and glucose-lowering effects in a single molecule. Lipaglyn has an active ingredient Saroglitazar and is the world’s first glitazar to be approved anywhere in the world.

Discovered by Zydus Research Centre, the dedicated NCE research arm of Zydus Cadilla – the Ahmedabad headquartered group.

The drug has been approved for launch in India by the Drug Controller General of India (DCGI)and is expected to be in the market by 2014.